Retatrutide's Phase 2 trial data (Jastreboff et al., NEJM 2023) identified a side-effect profile broadly consistent with other incretin-based therapies: Gastrointestinal : Nausea, vomiting, diarrhoea, and constipation were the most commonly reported adverse effects, particularly during dose escalation
Essentially, CJC-1295 + Ipamorelin therapy signals your pituitary gland to release more growth hormone in a pulsatile, physiologic way
The body stores some B12 in the liver, but excess amounts are flushed out of the body through urine
Some patients report a pale or yellowish tinge to the skin, and glossitis (a sore, red tongue) may develop
Heres why our clients trust us: Experienced Medical Professionals : Our founder, Amparo Robles, MSN, FNP-BC, brings over 15 years of healthcare experience